Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Addex Therapeutics logo — Allosteric modulators for Human Health

Addex Therapeutics

Allosteric modulators for Human Health

Founded 2002 Switzerland Plan-les-ouates, Switzerland 19 employees Post-IPO Equity Total: $139.84M Biotechnology, Health Care +1

General Information

Company Name Addex Therapeutics
Founded Year 2002
Location Switzerland Plan-les-ouates, Switzerland
Founders / Decision Makers
Team member
Employees 19
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Addex Therapeutics. To contact Addex Therapeutics, visit addextherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Addex Therapeutics compare?

A PDF of Addex Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Addex Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Addex Therapeutics

Addex Therapeutics is a Swiss-based biotechnology company founded in 2002 and listed on the SIX Swiss Exchange and NASDAQ Capital Market under the ticker symbol "ADXN." The company focuses on the development and commercialization of allosteric modulators, a novel class of orally available small molecule drugs, for the treatment of neurological disorders. Their lead drug candidate, dipraglurant, a negative allosteric modulator for Parkinson’s disease levodopa induced dyskinesia (PD-LID), is positioned to begin a pivotal registration clinical trial in H1 2021. Furthermore, Addex is exploring dipraglurant's therapeutic potential in treating blepharospasm and other conditions. The company's collaboration with Janssen Pharmaceuticals, Inc. has led to the development of ADX71149, a positive allosteric modulator for the treatment of epilepsy. Addex has also licensed its GABAB PAM program to Indivior PLC for the treatment of addiction. Additionally, they have various preclinical programs targeting different neurological and psychiatric disorders. In their most recent funding round, the company secured a $2.10M post-IPO equity investment on 31 January 2024. With their innovative approach and diverse pipeline, Addex Therapeutics presents an intriguing opportunity for investors interested in the biotechnology and pharmaceutical sectors.

Business keywords: Allosteric modulators, Neurological disorders, Pharmaceutical, Clinical-stage, Drug development, Parkinson's disease, Dyskinesia, Epilepsy, Addiction treatment, Preclinical programs, mGlu receptors, GABAB receptors, PTSD, Neurodegenerative disorders, NASDAQ

Funding Rounds & Investors (15)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $2.10M -
31 Jan 2024
Grant €4.00M -
20 Sep 2023
Post IPO Equity Fr.2.70M 1
Indivior
03 Aug 2023
Post IPO Equity $5.00M -
05 Apr 2023
Post IPO Equity $4.20M 1
Armistice Master Fund LTV
22 Jul 2022
Post IPO Equity $11.50M -
11 Jan 2021
Grant Undisclosed 1
Innosuisse
Innosuisse
27 Aug 2020
Post IPO Equity Fr.40.00M -
29 Mar 2018
Grant $835.00K 1
The Michael J. Fox Foundation for Parkinson's Research
The Michael J. Fox Foundation for Parkinson's Research
31 Jan 2017
Post IPO Equity Fr.3.20M 2
Biotechnology Value Fund, Armistice Capital
09 Aug 2013

View All 15 Funding Rounds

Addex Therapeutics Alternatives & Competitors

View All Alternatives
Addex Therapeutics vs
Gain Therapeutics
Gain Therapeutics United States

Unfolding the next generation of allosteric small molecule therapies to meet patient needs

IPO
26 employees
Biotechnology, Pharmaceutical
Compare Addex Therapeutics vs Gain Therapeutics
Addex Therapeutics vs
Allyx Therapeutics
Allyx Therapeutics United States

Protecting Synapses and Reversing Neurodegeneration

Venture round
5 employees
Biotechnology, Health Care
Addex Therapeutics vs
Newron Pharmaceuticals SpA
Newron Pharmaceuticals SpA Italy

The Specialist in CNS Drug Development

Post-IPO Equity
23 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Addex Therapeutics

Allosteric modulators for Human Health
Addex Therapeutics was founded in 2002.
Addex Therapeutics is headquartered in Plan-les-ouates, Switzerland.
Addex Therapeutics operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Allosteric modulators, Neurological disorders, Pharmaceutical and Clinical-stage.
Addex Therapeutics has approximately 19 employees.
Addex Therapeutics has completed 15 funding rounds, raising a total of $139.84M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Addex Therapeutics include Gain Therapeutics, Allyx Therapeutics, Newron Pharmaceuticals SpA, Asceneuron SA, Satori Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Addex Therapeutics and Gain Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Addex Therapeutics, https://bouncewatch.com/company/addex-therapeutics, updated 1 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout